Deutsche Bank AG Has $2.51 Million Position in Celldex Therapeutics, Inc. $CLDX

Key Points

• Deutsche Bank AG increased its stake in Celldex Therapeutics by 13.8% during the first quarter, holding 138,289 shares valued at approximately $2.51 million.
• Celldex Therapeutics reported a quarterly loss of ($0.85) EPS, surpassing estimates, but generated only $0.73 million in revenue, below expectations of $1.13 million.
• Analysts have lowered their price targets for Celldex Therapeutics, with an average target price of $51.75 and a general rating of "Moderate Buy."

Deutsche Bank AG lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 138,289 shares of the biopharmaceutical company's stock after purchasing an additional 16,788 shares during the period. Deutsche Bank AG owned 0.21% of Celldex Therapeutics worth $2,510,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in shares of Celldex Therapeutics by 103.3% during the 4th quarter. JPMorgan Chase & Co. now owns 85,545 shares of the biopharmaceutical company's stock worth $2,162,000 after purchasing an additional 43,470 shares during the period. Invesco Ltd. increased its holdings in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after purchasing an additional 871 shares during the period. Renaissance Technologies LLC bought a new position in shares of Celldex Therapeutics during the 4th quarter worth about $3,452,000. Barclays PLC increased its holdings in shares of Celldex Therapeutics by 9.6% during the 4th quarter. Barclays PLC now owns 142,914 shares of the biopharmaceutical company's stock worth $3,611,000 after purchasing an additional 12,533 shares during the period. Finally, Guggenheim Capital LLC bought a new position in shares of Celldex Therapeutics during the 4th quarter worth about $601,000.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CLDX. Canaccord Genuity Group dropped their price objective on shares of Celldex Therapeutics from $64.00 to $62.00 and set a "buy" rating on the stock in a report on Wednesday. UBS Group lowered their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. HC Wainwright lowered their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating on the stock in a research note on Wednesday. The Goldman Sachs Group lowered their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Finally, Wells Fargo & Company lowered their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating on the stock in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.67.

Celldex Therapeutics Stock Up 2.0%

NASDAQ:CLDX traded up $0.44 on Friday, reaching $22.46. The stock had a trading volume of 1,797,765 shares, compared to its average volume of 1,313,527. The company has a market capitalization of $1.49 billion, a P/E ratio of -7.46 and a beta of 1.22. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The stock has a fifty day moving average price of $22.12 and a 200-day moving average price of $20.67.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.01. The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.